The largest study to date suggests that patients at high risk for heart attacks and strokes should begin immediate treatment with a combination of a statin and ezetimibe. The largest study to date exa ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

The pills are fairly cheap to obtain and could save a lot of people from common health issues, but they might not be the ...

Plant sterols and stanols share a structural resemblance to cholesterol, allowing them to compete for absorption in the ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

For LDL-C levels below 55 mg/dL there was an 18% risk reduction for both all-cause dementia and ADRD. In those with LDL-C ...